Sign in
WithdrawnNo phase

Parathyroid Allotransplantation in Medically Refractory Hypoparathyroidism

Key facts

Who runs it
University of Alabama at Birmingham
Where
Birmingham, United StatesSee the site
Trial code
Status
Withdrawn
Starts
Jul 2027
Expected to end
Jan 2030
Type of study
Interventional
Treatments tested
  • Parathyroid Allotransplant
Record updated
21 August 2026
Why it stopped
Regulatory challenges

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 15 criteriaShow less

Who can take part

  • Individual diagnosed with hypocalcemia secondary to; Hypoparathyroidism:; Prior anterior cervical neck surgery resulting in hypoparathyroidism; Congenital absence or malformation of parathyroid glands during development; Presence of hypoparathyroidism for at least one year; Failure of medical treatment for hypocalcemia, including need for IV calcium, with negative impact on quality of life and daily function; Age 18-80 years; Lives in the greater Birmingham region for the duration of the trial; Fluent in the English Language; Willing to comply with screening, protocol and all required procedures

Who cannot take part

  • Current smoker (smoking cessation must have occurred 3 months prior to enrollment)
  • Resources deemed inadequate to support necessary post-transplant care
  • Any active malignancy, except non-melanoma skin cancer
  • History of significant psychiatric illness
  • Allergy, hypersensitivity, or intolerance of expected immunosuppressive agents (i.e. Thymoglobulin®, tacrolimus, etc.)
  • Documented history of gross non-adherence to medical therapies
  • Significant functional/cognitive impairment without reliable caregiver
  • Presence of active documented systemic infection or recent systemic infection within the past 3 months
  • Seropositivity for HIV, HBV core antibody or antigen, HCV, HTLV-1
  • Psychosocial problems (including alcoholism, drug abuse, documented behavioral disorders)
  • History of ischemic cardiomyopathy with ejection fraction <20%, uncontrolled diabetes mellitus (Hgb A1c >10), thrombophilia or other clotting or bleeding disorders, significant heart, liver, kidney or central nervous system disease
  • Dependence on nursing home or other long-term care provider
  • Severe osteoporosis
  • Chemical and/or alcohol dependency or abuse

Where in United States

  • University of Alabama at BirminghamBirmingham, United States

About the trial

What the trial wants to find out

Options for treatment of severe, refractory hypocalcemia are limited for the thousands of patients in the United States who suffer from hypoparathyroidism. Parathyroid allotransplantation is an emerging treatment that provides hope for these individuals. Currently, this therapy has only been successfully provided by a few centers in the world. In the UAB PATH trial, we propose to become one of the few centers worldwide to successfully achieve parathyroid allotransplantation in transplant-naïve patients.

Treatments tested

  • Parathyroid Allotransplant

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Record updated
21 August 2026